Avantor, Inc.

NYSE:AVTR

Medical - Instruments & Supplies

Healthcare
$15.37 +0.69%

+$0.07 today

Market cap
$10.41B
Beta
0.96
P/E (TTM)
-11.7
EPS (TTM)
-$0.81
52W Low $7.27High $15.93

Volume 5.94M

Average 9.44M

AVTR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Avantor, Inc.NYSE: AVTR

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development remains negative

Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How AVTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Research & development amounts to 0.0% of revenue for AVTR, versus a peer median of 6.3%.
AVTR Competitors
Research & Development for AVTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$1.67B USD+4.2%+1.5%6.5%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$261.1M USD-14.3%+0.0%10.1%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$74.4M USD+7.2%+8.3%2.2%
RGENRepligen CorporationLTM Jun 2026$55.23M USD+14.4%+7.2%7.0%
AZTAAzenta, Inc.LTM Sep 2026$37.92M USD+31.1%+3.7%6.1%
STVNStevanato Group S.p.A.LTM Jun 2026€25.44M EUR+5.3%-10.8%2.1%
BLFSBioLife Solutions, Inc.LTM Mar 2026$8.14M USD+5.5%-20.0%8.2%
AVTRAvantor, Inc.LTM Jun 2026$0 USD——0.0%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding AVTR) —+5.5%+1.5%6.3%

Competitors are the stored peer set for AVTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.39B7.51B6.97B6.78B6.55B
Cost of Revenue4.88B4.91B4.6B4.5B4.41B
Gross Profit2.5B2.6B2.36B2.28B2.14B
Gross Margin33.9%34.6%33.9%33.6%32.7%
Research & Development00000
Selling, General & Admin1.53B1.47B1.51B1.64B1.6B
Operating Expenses1.53B1.47B1.67B1.19B2.39B
Depreciation & Amortization379.2M405.5M402.3M405.5M410.2M
EBITDA1.35B1.52B1.1B1.48B138.7M
EBITDA Margin18.3%20.3%15.8%21.8%2.1%
Operating Income972.2M1.13B696.4M1.08B(246.2M)
Operating Margin13.2%15.0%10.0%16.0%-3.8%
Interest Income00000
Interest Expense217.4M265.8M284.8M218.8M169.8M
Other Income / Expenses(219.2M)(279.1M)(285.9M)(230.9M)(195.1M)
Income Before Tax753M851.1M410.5M853.9M(441.3M)
Pre-Tax Margin10.2%11.3%5.9%12.6%-6.7%
Income Tax Expense180.4M164.6M89.4M142.4M88.9M
Net Income572.6M686.5M321.1M711.5M(530.2M)
Net Margin7.8%9.1%4.6%10.5%-8.1%
EPS (Basic)0.861.020.481.05(0.78)
EPS (Diluted)0.851.010.471.04(0.78)
Weighted Avg Shares590.5M650.9M675.6M680.3M678M
Weighted Avg Shares (Diluted)599.6M679.4M678.4M681.9M679.3M

Avantor, Inc.

NYSE:AVTR

Intrinsic Alpha fair value

Locked

Current Price

$15.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.